Leerink Swann Reiterates “Outperform” Rating for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE:JNJ)‘s stock had its “outperform” rating reiterated by research analysts at Leerink Swann in a research report issued on Wednesday, The Fly reports. They currently have a $160.00 price target on the stock, down from their prior price target of $175.00. Leerink Swann’s target price indicates a potential upside of 25.44% from the company’s current price. Leerink Swann also issued estimates for Johnson & Johnson’s FY2018 earnings at $8.15 EPS, Q1 2019 earnings at $2.27 EPS and Q3 2019 earnings at $2.12 EPS. The analysts noted that the move was a valuation call.

JNJ has been the subject of several other reports. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. Jefferies Group set a $153.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday, April 13th. Vetr cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 target price for the company. in a research note on Monday, March 26th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $142.98.

How to Become a New Pot Stock Millionaire

Shares of JNJ stock opened at $127.55 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. The company has a market capitalization of $350,226.03, a P/E ratio of 17.47, a P/E/G ratio of 2.08 and a beta of 0.74. Johnson & Johnson has a 1 year low of $121.35 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The firm’s revenue for the quarter was up 12.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.83 earnings per share. analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.

In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.22% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in JNJ. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares during the period. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Bank of New York Mellon Corp increased its holdings in Johnson & Johnson by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after purchasing an additional 130,437 shares during the period. Geode Capital Management LLC increased its holdings in Johnson & Johnson by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 30,521,157 shares of the company’s stock valued at $4,256,109,000 after purchasing an additional 939,488 shares during the period. Finally, FMR LLC increased its holdings in Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares during the period. Institutional investors own 67.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Leerink Swann Reiterates “Outperform” Rating for Johnson & Johnson (JNJ)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/20/leerink-swann-reiterates-outperform-rating-for-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

The Fly

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply